BRISTOL MYERS SQUIBB
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
- First Posted Date
- 2007-06-01
- Last Posted Date
- 2017-02-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 547
- Registration Number
- NCT00481247
- Locations
- 🇺🇸
Molecular Md, Portland, Oregon, United States
🇹🇷Local Institution, Kayseri, Turkey
Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2011-11-30
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 25
- Registration Number
- NCT00479583
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University Of Alabama At Birmingham, Birmingham, Alabama, United States
🇫🇷Local Institution, Villejuif, France
A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2009-09-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 35
- Registration Number
- NCT00461110
- Locations
- 🇺🇸
Thomas Jefferson Univ Hospital, Philadelphia, Pennsylvania, United States
🇺🇸University Of Texas Southwestern Medical Center, Dallas, Texas, United States
🇺🇸The Cancer Institute Of New Jersey, New Brunswick, New Jersey, United States
A Multiple-Dose Study of Sinemet® CR (Carbidopa/Levodopa) in Healthy Subjects
- Conditions
- First Posted Date
- 2007-04-17
- Last Posted Date
- 2008-08-14
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT00460954
- Locations
- 🇨🇦
Local Institution, Toronto, Ontario, Canada
Study of Apixaban for the Prevention of Thrombosis-related Events in Patients With Acute Medical Illness
- Conditions
- Interventions
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2015-12-08
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 6758
- Registration Number
- NCT00457002
- Locations
- 🇺🇸
Pulmonary & Critical Care Of Atlanta, Atlanta, Georgia, United States
🇺🇸Atlanta Institute For Medical Research, Inc, Atlanta, Georgia, United States
🇺🇸Johns Hopkins University School Of Medicine, Baltimore, Maryland, United States
Study to Assess Effectiveness of Giving Combination of Standard Chemotherapy Drugs Versus Combination of Standard Chemotherapy and New Drug Ixabepilone When Given Before Surgical Removal of Early Stage Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 384
- Registration Number
- NCT00455533
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Florida Cancer Research Institute, Davie, Florida, United States
🇺🇸Albert Einstein Cancer Center, Bronx, New York, United States
A Phase II Study of Belatacept (BMS-224818) With a Steroid-free Regimen in Subjects Undergoing Kidney Transplantation
- Conditions
- Interventions
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2014-06-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 93
- Registration Number
- NCT00455013
- Locations
- 🇺🇸
Northwestern University Feinberg School Of Medicine, Chicago, Illinois, United States
🇺🇸Denver Nephrology, Pc, Denver, Colorado, United States
🇺🇸University Of Colorado Health Sciences Center, Denver, Colorado, United States
Expanded Access for Dasatinib
- First Posted Date
- 2007-04-02
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00454753
Phase I Study of Dasatinib (BMS-354825) and Capecitabine for Women With Advanced Breast Cancer
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 52
- Registration Number
- NCT00452673
- Locations
- 🇪🇸
Local Institution, Sevilla, Spain
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸City Of Hope National Medical Center, Duarte, California, United States
Study of an Investigational Drug for the Prevention of Thrombosis-related Events Following Knee Replacement Surgery
- Conditions
- Interventions
- First Posted Date
- 2007-03-27
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 3221
- Registration Number
- NCT00452530
- Locations
- 🇬🇧
Local Institution, Epsom, Surrey, United Kingdom